Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
Roland E. Schmieder(Universitätsklinikum Erlangen), Murray Esler(Baker Heart and Diabetes Institute), Markus P. Schlaich(The University of Western Australia), Paul A. Sobotka(The Ohio State University), Henry Krum(Australian Regenerative Medicine Institute)
Cited by 2,239
Related Papers
Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study
|The Lancet|2009|2.1k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Targeted Anticytokine Therapy in Patients With Chronic Heart Failure
|Circulation|2004|1.2k
Aliskiren, ALTITUDE, and the Implications for ATMOSPHERE
|European Journal of Heart Failure|2012|1.1k